Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A J Duncton

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Organic Letters|July 10, 2008
Preparation of aryloxetanes and arylazetidines by use of an alkyl-aryl suzuki couplingMatthew A J Duncton, M Angels Estiarte, Darlene Tan, et al.
ACS Medicinal Chemistry Letters|December 20, 2023
Tuning the Reactivity of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Optimal <i>in Vivo</i> EfficacyVadim Markovtsov, Matthew A J Duncton, Art Bagos, et al.
International Journal of Molecular Sciences|December 9, 2023
A New Drug Discovery Platform: Application to DNA Polymerase Eta and Apurinic/Apyrimidinic Endonuclease 1Debanu Das, Matthew A J Duncton, Taxiarchis M Georgiadis, et al.
Bioorganic & Medicinal Chemistry Letters|August 4, 2015
Identification of orally-bioavailable antagonists of the TRPV4 ion-channelZhi-Liang Wei, Margaret T Nguyen, Donogh J R O'Mahony, et al.
Bioorganic & Medicinal Chemistry Letters|August 5, 2006
Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinaseLeon Smith, Wai C Wong, Alexander S Kiselyov, et al.
Science Translational Medicine|October 11, 2023
Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinomaKavita Y Sarin, John Kincaid, Brittney Sell, et al.
Bioorganic & Medicinal Chemistry|December 23, 2008
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2Matthew A J Duncton, Eugene L Piatnitski Chekler, Reeti Katoch-Rouse, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Organic Letters|July 10, 2008
Preparation of aryloxetanes and arylazetidines by use of an alkyl-aryl suzuki couplingMatthew A J Duncton, M Angels Estiarte, Darlene Tan, et al.
ACS Medicinal Chemistry Letters|December 20, 2023
Tuning the Reactivity of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Optimal <i>in Vivo</i> EfficacyVadim Markovtsov, Matthew A J Duncton, Art Bagos, et al.
International Journal of Molecular Sciences|December 9, 2023
A New Drug Discovery Platform: Application to DNA Polymerase Eta and Apurinic/Apyrimidinic Endonuclease 1Debanu Das, Matthew A J Duncton, Taxiarchis M Georgiadis, et al.
Bioorganic & Medicinal Chemistry Letters|August 4, 2015
Identification of orally-bioavailable antagonists of the TRPV4 ion-channelZhi-Liang Wei, Margaret T Nguyen, Donogh J R O'Mahony, et al.
Bioorganic & Medicinal Chemistry Letters|August 5, 2006
Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinaseLeon Smith, Wai C Wong, Alexander S Kiselyov, et al.
Science Translational Medicine|October 11, 2023
Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinomaKavita Y Sarin, John Kincaid, Brittney Sell, et al.
Bioorganic & Medicinal Chemistry|December 23, 2008
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2Matthew A J Duncton, Eugene L Piatnitski Chekler, Reeti Katoch-Rouse, et al.
Pageof 3